157 related articles for article (PubMed ID: 19110306)
1. Cathepsin B protein levels in endometrial cancer: Potential value as a tumour biomarker.
Devetzi M; Scorilas A; Tsiambas E; Sameni M; Fotiou S; Sloane BF; Talieri M
Gynecol Oncol; 2009 Mar; 112(3):531-6. PubMed ID: 19110306
[TBL] [Abstract][Full Text] [Related]
2. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
[TBL] [Abstract][Full Text] [Related]
3. Determination of cathepsin B expression may offer additional prognostic information for ovarian cancer patients.
Scorilas A; Fotiou S; Tsiambas E; Yotis J; Kotsiandri F; Sameni M; Sloane BF; Talieri M
Biol Chem; 2002; 383(7-8):1297-303. PubMed ID: 12437120
[TBL] [Abstract][Full Text] [Related]
4. May cathepsin D immunoreactivity be used as a prognostic factor in endometrial carcinomas? A comparative immunohistochemical study.
Saygili U; Koyuncuoglu M; Altunyurt S; Guclu S; Uslu T; Erten O
Gynecol Oncol; 2001 Oct; 83(1):20-4. PubMed ID: 11585409
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic significance and clinic utility of serum and immunohistochemical cathepsin B levels in colorectal cancer].
Padilla D; Cubo T; Molina JM; García M; De la Osa G; Palomino T; Pardo R; Martín J; Arévalo E; Hernández Calvo J
An Med Interna; 2003 Oct; 20(10):521-5. PubMed ID: 14585038
[TBL] [Abstract][Full Text] [Related]
6. [The prognostic value of cathepsin D in endometrial carcinoma].
Köhler U; Langanke D; Sorger D; Martin R; Bilek K
Zentralbl Gynakol; 1995; 117(3):148-52. PubMed ID: 7740849
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous expression of Cathepsins B and K in pulmonary adenocarcinomas and squamous cell carcinomas predicts poor recurrence-free and overall survival.
Cordes C; Bartling B; Simm A; Afar D; Lautenschläger C; Hansen G; Silber RE; Burdach S; Hofmann HS
Lung Cancer; 2009 Apr; 64(1):79-85. PubMed ID: 18760860
[TBL] [Abstract][Full Text] [Related]
8. Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer.
Poincloux L; Durando X; Seitz JF; Thivat E; Bardou VJ; Giovannini MH; Parriaux D; Barriere N; Giovannini M; Delpero JR; Monges G
Surg Oncol; 2009 Dec; 18(4):357-65. PubMed ID: 19027288
[TBL] [Abstract][Full Text] [Related]
9. Aberrations in the progesterone receptor gene and the risk of recurrent endometrial carcinoma.
Pijnenborg JM; Romano A; Dam-de Veen GC; Dunselman GA; Fischer DC; Groothuis PG; Kieback DG
J Pathol; 2005 Apr; 205(5):597-605. PubMed ID: 15726651
[TBL] [Abstract][Full Text] [Related]
10. Heparanase expression in endometrial cancer: analysis of immunohistochemistry.
Inamine M; Nagai Y; Hirakawa M; Mekaru K; Yagi C; Masamoto H; Aoki Y
J Obstet Gynaecol; 2008 Aug; 28(6):634-7. PubMed ID: 19003663
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
Suthipintawong C; Wejaranayang C; Vipupinyo C
J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
[TBL] [Abstract][Full Text] [Related]
12. P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up.
Theodoropoulos GE; Karafoka E; Papailiou JG; Stamopoulos P; Zambirinis CP; Bramis K; Panoussopoulos SG; Leandros E; Bramis J
Anticancer Res; 2009 Feb; 29(2):785-91. PubMed ID: 19331236
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival.
Pertschuk LP; Masood S; Simone J; Feldman JG; Fruchter RG; Axiotis CA; Greene GL
Gynecol Oncol; 1996 Oct; 63(1):28-33. PubMed ID: 8898164
[TBL] [Abstract][Full Text] [Related]
14. Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma.
Talieri M; Papadopoulou S; Scorilas A; Xynopoulos D; Arnogianaki N; Plataniotis G; Yotis J; Agnanti N
Cancer Lett; 2004 Mar; 205(1):97-106. PubMed ID: 15036666
[TBL] [Abstract][Full Text] [Related]
15. Expression of the serine protease hepsin and clinical outcome of human endometrial cancer.
Matsuo T; Nakamura K; Takamoto N; Kodama J; Hongo A; Abrzua F; Nasu Y; Kumon H; Hiramatsu Y
Anticancer Res; 2008; 28(1A):159-64. PubMed ID: 18383840
[TBL] [Abstract][Full Text] [Related]
16. Expression of Ret finger protein correlates with outcomes in endometrial cancer.
Tsukamoto H; Kato T; Enomoto A; Nakamura N; Shimono Y; Jijiwa M; Asai N; Murakumo Y; Shibata K; Kikkawa F; Takahashi M
Cancer Sci; 2009 Oct; 100(10):1895-901. PubMed ID: 19650860
[TBL] [Abstract][Full Text] [Related]
17. Endometrial carcinoma expresses an increased cathepsin B/D ratio.
Bradley WH; Lima PH; Rodgers L; Blomquist CH; Downs LS
Gynecol Oncol; 2008 Jan; 108(1):84-9. PubMed ID: 17980407
[TBL] [Abstract][Full Text] [Related]
18. Total and lipid-bound plasma sialic acid as diagnostic markers in colorectal cancer patients: correlation with cathepsin B expression in progression to Dukes stage.
Sebzda T; Saleh Y; Gburek J; Warwas M; Andrzejak R; Siewinski M; Rudnicki J
J Exp Ther Oncol; 2006; 5(3):223-9. PubMed ID: 16528972
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of tumor angiogenesis and thymidine phosphorylase tissue expression in patients with endometrial cancer.
Mazurek A; Kuc P; Terlikowski S; Laudanski T
Neoplasma; 2006; 53(3):242-6. PubMed ID: 16652195
[TBL] [Abstract][Full Text] [Related]
20. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
